MedTrace Logo

Safety and Efficacy of Ketoconazole 2% Foam in the Treatment of Pityrosporum Folliculitis

NCT00824863 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2014-08-21

No results posted yet for this study

Summary

Pityrosporum folliculitis presents as fine superficial follicular pustules and papules on the trunk and upper extremities. Ketoconazole 2% foam was recently approved for the treatment of seborrheic dermatitis in immunocompetent patients 12 years and older. Ketoconazole 2% foam is felt to work by reducing the number of pityrosporum yeast organisms. Safety and efficacy of ketoconazole 2% foam treatment for this fungal infections has not been established. This study is to demonstrate efficacy and safety in the treatment of pityrosporum folliculitis.

Conditions

  • Pityrosporum Folliculitis

Interventions

DRUG

ketoconazole 2% foam

topical antifungal foam to be applied to the folliculitis BID for 2-4 weeks.

Sponsors & Collaborators

  • Wayne Fujita, M.D.

    lead INDIV

Principal Investigators

  • Wayne H. Fujita, M.D. · Private Practice

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-12-31
Primary Completion
2010-05-31
Completion
2010-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00824863 on ClinicalTrials.gov